Pre-Op Osimertinib in Lung Cancer Leads to More Major Pathologic Responses

(MedPage Today) — CHICAGO — Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates compared with chemotherapy alone in resectable EGFR-mutant non-small cell lung cancer…